163 related articles for article (PubMed ID: 8067751)
1. Reversal of clavulanate resistance conferred by a Ser-244 mutant of TEM-1 beta-lactamase as a result of a second mutation (Arg to Ser at position 164) that enhances activity against ceftazidime.
Imtiaz U; Manavathu EK; Mobashery S; Lerner SA
Antimicrob Agents Chemother; 1994 May; 38(5):1134-9. PubMed ID: 8067751
[TBL] [Abstract][Full Text] [Related]
2. Characterisation of a unique ceftazidime-hydrolysing beta-lactamase, TEM-E2.
Payne DJ; Marriott MS; Amyes SG
J Med Microbiol; 1990 Jun; 32(2):131-4. PubMed ID: 2192063
[TBL] [Abstract][Full Text] [Related]
3. Selective ceftazidime resistance in Escherichia coli: association with changes in outer membrane protein.
Bakken JS; Sanders CC; Thomson KS
J Infect Dis; 1987 Jun; 155(6):1220-5. PubMed ID: 3553348
[TBL] [Abstract][Full Text] [Related]
4. Selection and characterization of beta-lactam-beta-lactamase inactivator-resistant mutants following PCR mutagenesis of the TEM-1 beta-lactamase gene.
Vakulenko SB; Geryk B; Kotra LP; Mobashery S; Lerner SA
Antimicrob Agents Chemother; 1998 Jul; 42(7):1542-8. PubMed ID: 9660980
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of TEM-2 beta-lactamase from Escherichia coli by clavulanic acid: observation of intermediates by electrospray ionization mass spectrometry.
Brown RP; Aplin RT; Schofield CJ
Biochemistry; 1996 Sep; 35(38):12421-32. PubMed ID: 8823177
[TBL] [Abstract][Full Text] [Related]
6. Construction and characterization of mutants of the TEM-1 beta-lactamase containing amino acid substitutions associated with both extended-spectrum resistance and resistance to beta-lactamase inhibitors.
Stapleton PD; Shannon KP; French GL
Antimicrob Agents Chemother; 1999 Aug; 43(8):1881-7. PubMed ID: 10428907
[TBL] [Abstract][Full Text] [Related]
7. Characterization of a new TEM-type beta-lactamase resistant to clavulanate, sulbactam, and tazobactam in a clinical isolate of Escherichia coli.
Blazquez J; Baquero MR; Canton R; Alos I; Baquero F
Antimicrob Agents Chemother; 1993 Oct; 37(10):2059-63. PubMed ID: 8257123
[TBL] [Abstract][Full Text] [Related]
8. Back mutations to the TEM-1 beta-lactamase from TRC-1 lead to restored sensitivity to clavulanic acid.
Thomson CJ; Amyes SG
J Med Microbiol; 1995 Jun; 42(6):429-32. PubMed ID: 7791208
[TBL] [Abstract][Full Text] [Related]
9. Emergence of clinical isolates of Escherichia coli producing TEM-1 derivatives or an OXA-1 beta-lactamase conferring resistance to beta-lactamase inhibitors.
Zhou XY; Bordon F; Sirot D; Kitzis MD; Gutmann L
Antimicrob Agents Chemother; 1994 May; 38(5):1085-9. PubMed ID: 8067742
[TBL] [Abstract][Full Text] [Related]
10. Clinical isolates of Escherichia coli producing multiple TEM mutants resistant to beta-lactamase inhibitors.
Sirot D; Chanal C; Henquell C; Labia R; Sirot J; Cluzel R
J Antimicrob Chemother; 1994 Jun; 33(6):1117-26. PubMed ID: 7928805
[TBL] [Abstract][Full Text] [Related]
11. A complex mutant of TEM-1 beta-lactamase with mutations encountered in both IRT-4 and extended-spectrum TEM-15, produced by an Escherichia coli clinical isolate.
Sirot D; Recule C; Chaibi EB; Bret L; Croize J; Chanal-Claris C; Labia R; Sirot J
Antimicrob Agents Chemother; 1997 Jun; 41(6):1322-5. PubMed ID: 9174192
[TBL] [Abstract][Full Text] [Related]
12. Resistance to beta-lactamase inhibitor protein does not parallel resistance to clavulanic acid in TEM beta-lactamase mutants.
Schroeder WA; Locke TR; Jensen SE
Antimicrob Agents Chemother; 2002 Nov; 46(11):3568-73. PubMed ID: 12384366
[TBL] [Abstract][Full Text] [Related]
13. Cefotaxime and ceftazidime-resistant Escherichia coli isolate producing TEM-15 beta-lactamase from a Tunisian hospital.
Chouchani C; Ben-Achour N; M'charek A; Belhadj O
C R Biol; 2007 Aug; 330(8):565-70. PubMed ID: 17637436
[TBL] [Abstract][Full Text] [Related]
14. Clavulanic acid inactivation of SHV-1 and the inhibitor-resistant S130G SHV-1 beta-lactamase. Insights into the mechanism of inhibition.
Sulton D; Pagan-Rodriguez D; Zhou X; Liu Y; Hujer AM; Bethel CR; Helfand MS; Thomson JM; Anderson VE; Buynak JD; Ng LM; Bonomo RA
J Biol Chem; 2005 Oct; 280(42):35528-36. PubMed ID: 15987690
[TBL] [Abstract][Full Text] [Related]
15. A new TEM-derived extended-spectrum beta-lactamase (TEM-91) with an R164C substitution at the omega-loop confers ceftazidime resistance.
Kurokawa H; Shibata N; Doi Y; Shibayama K; Kamachi K; Yagi T; Arakawa Y
Antimicrob Agents Chemother; 2003 Sep; 47(9):2981-3. PubMed ID: 12937007
[TBL] [Abstract][Full Text] [Related]
16. TEM-4, a new plasmid-mediated beta-lactamase that hydrolyzes broad-spectrum cephalosporins in a clinical isolate of Escherichia coli.
Paul GC; Gerbaud G; Bure A; Philippon AM; Pangon B; Courvalin P
Antimicrob Agents Chemother; 1989 Nov; 33(11):1958-63. PubMed ID: 2692515
[TBL] [Abstract][Full Text] [Related]
17. Mutant TEM beta-lactamase producing resistance to ceftazidime, ampicillins, and beta-lactamase inhibitors.
Vakulenko S; Golemi D
Antimicrob Agents Chemother; 2002 Mar; 46(3):646-53. PubMed ID: 11850243
[TBL] [Abstract][Full Text] [Related]
18. Variants of β-lactamase KPC-2 that are resistant to inhibition by avibactam.
Papp-Wallace KM; Winkler ML; Taracila MA; Bonomo RA
Antimicrob Agents Chemother; 2015 Jul; 59(7):3710-7. PubMed ID: 25666153
[TBL] [Abstract][Full Text] [Related]
19. Selection of variants of the TEM-1 beta-lactamase, encoded by a plasmid of clinical origin, with increased resistance to beta-lactamase inhibitors.
Thomson CJ; Amyes SG
J Antimicrob Chemother; 1993 May; 31(5):655-64. PubMed ID: 8392995
[TBL] [Abstract][Full Text] [Related]
20. Aspartic acid for asparagine substitution at position 276 reduces susceptibility to mechanism-based inhibitors in SHV-1 and SHV-5 beta-lactamases.
Giakkoupi P; Tzelepi E; Legakis NJ; Tzouvelekis LS
J Antimicrob Chemother; 1999 Jan; 43(1):23-9. PubMed ID: 10381097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
